New drugs and treatments have to undergo a slew of studies and tests to help patients who need cures for their conditions. Clinical trials lay the foundation of efficacy and safety for new therapies and drugs. However, the process could be herculean for trial coordinators and pharmaceutical companies that dedicate a great deal of time,…
FARGO, ND, April 15, 2021 /EINPresswire.com/ — RxE2 Inc. announced today that it has completed the acquisition of Habitu Ltd. The details of the agreement were disclosed in a press release on January 11, 2021 Here is the link to the press release with the specifics of how Habitu’s AI-powered technology platform will enhance RxE2’s…
Gerald Finken, the founder of RxE2 and E2 services explains how he is using an efficient clinical supply chain process to deliver affordable, effective, and quality services. Gerald is following this one simple rule of disruptive innovation to improve patient centered care. He says, “Believe in your idea, have faith, and don’t go against collective…
Join us for Everyone Everywhere Episode 04; The Role and Impact of the CTRP®, to hear from Dr. Kristina Schlecht about the knowledge she has gained through firsthand experience as a pharmacist, and how she is leading our industry forward as Chief Pharmacy Officer of RxE2. Connect with Tina on LinkedIn: https://www.linkedin.com/in/tina-schlecht/ Connect with Gerald on…
This Fierce Biotech webinar focuses on how a pharmacist-led clinical trial model impacts the six key areas most relevant to clinical trials in today’s COVID and Decentralized Clinical Trial environment: • Regulations – GMP and GCP regulations versus state healthcare regulations • Recruiting – Clinical research participation as a healthcare option for all patients…
Fargo, ND, February 2, 2021— RxE2 CEO and two-time USA Cycling Masters National Cycling Champion, Gerald Finken, is once again helping young cyclists. RxE2 announced today that it will donate $27,500 to support the youth programs of the NorthStar Development Cycling Club. Mr. Finken’s current contribution will help to support the: training of young cyclists,…
Topic: Progressing From the Traditional Clinical Trials Model to a Distributed Pharmacist-Led Model Based on AI and Service Subscriptions Connect with Gerald Finken on LinkedIn https://www.linkedin.com/in/gfinken/ Connect with Yaniv Zilberman on LinkedIn https://www.linkedin.com/in/yanivzilberman/…
Fargo, ND, January 11, 2021 — RxE2, which is bringing the practice of pharmacy to clinical research, announced today it has agreed to acquire Habitu, an Israeli-based technology company. Habitu focuses on people’s habits and behaviors to create a KyP engine enabled by artificial intelligence, improving patient outcomes by providing real time analyses of a…
Join Gerald Finken in a live conversation with Yaniv Zilberman CEO of Habitu, as they discuss how advanced technologies like AI can drive successful Pharmacist–Led Clinical Trials
U.S. State Laws Govern the Dispensing, Labeling, and Counseling Requirements for Investigational New Drugs When conducting clinical trials, sponsors have traditionally looked to 21 C.F.R. §312, and not state law, for guidance. Upon closer examination of state laws, however, it becomes clear that states throughout the country categorize Investigational New Drugs (“INDs”) as prescription drugs.…